Educating QUitline Callers About Lung Cancer Screening (EQUAL)
Population at Risk
About this trial
This is an interventional screening trial for Population at Risk focused on measuring lung cancer, lung cancer screening
Eligibility Criteria
Inclusion Criteria:
- enrolled in the quitline
- 50-80 years old
- >20-pack year smoking history
- never screened or >12 months since prior screen
- English speaking
- able to provide meaningful consent
- no family members in the same household enrolled in the trial
Exclusion Criterion:
- prior lung cancer
Sites / Locations
- Georgetown University Medical Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Web arm
Print Arm
The Should I Screen educational website, developed by our consultant, Rafael Meza, PhD, is available at no cost, is written at an 8th grade reading level, requires 15 minutes to use, and undergoes regular updates (https://shouldiscreen.com). The goal is to increase lung screening awareness and to encourage a shared decision making visit with a provider. Sections of the website include the benefits (the reduced likelihood of dying from lung cancer) and harms (false alarms, overdiagnosis, more testing, and invasive procedures) of screening, causes of lung cancer, methods to reduce lung cancer risk, and the lung cancer risk calculator. Improvements in knowledge have been demonstrated with individuals eligible for screening.
The Should I Screen print-based education (included with this IRB protocol) will be developed in Aim 1 and compared to the Should I Screen website in Aim 2. It will also be at the 8th grade level and will require 15 minutes to read. Although it will contain the same topics as the website, there is one inherent difference - it is not possible to include the interactive risk calculator in the print version. The print-based version will list all of the risk criteria that are included in the algorithm so that participants can see which ones apply to them. However, the risk calculator requires the computer algorithm to calculate a person's 6-year risk of developing lung cancer.